- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Capricor Therapeutics Inc (CAPR)
Capricor Therapeutics Inc stock price live, this page displays NASDAQ CAPR stock exchange data. View the CAPR premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Capricor Therapeutics Inc real time stock price chart below.
What Is the Capricor Therapeutics Inc Stock Price Today?
The Capricor Therapeutics Inc stock price today is 19.500.
What Is the Stock Symbol for Capricor Therapeutics Inc?
The stock symbol for Capricor Therapeutics Inc is "CAPR."
What Stock Exchange Does Capricor Therapeutics Inc Trade On?
Capricor Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Capricor Therapeutics Inc a Good Stock to Buy?
Determining whether Capricor Therapeutics Inc, or any stock, is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CAPR quote. (ISIN: US14070B3096)
What Is the Capricor Therapeutics Inc Stock Price Today?
The Capricor Therapeutics Inc stock price today is 19.500.
What Is the Stock Symbol for Capricor Therapeutics Inc?
The stock symbol for Capricor Therapeutics Inc is "CAPR."
What Stock Exchange Does Capricor Therapeutics Inc Trade On?
Capricor Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Capricor Therapeutics Inc a Good Stock to Buy?
Determining whether Capricor Therapeutics Inc, or any stock, is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CAPR quote. (ISIN: US14070B3096)
Fair Value
An estimate of a Capricor Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
18.930
20.170
52 wk Range
4.300
40.370
CAPR is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Capricor Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
18.93020.170
52 wk Range
4.30040.370
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
CAPR Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Capricor Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
53.600
Upside
+174.87%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Net income is expected to grow this year
- Capricor CFO Bergmann sells $732k in shares
- Investing.com
- Form 4 Capricor Therapeutics Inc For: 29 June
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Buy
Moving Averages
Sell
Analyst Ratings
10 Buy
0 Hold
0 Sell
Ratings:
10 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 53.600
(+174.87% Upside)
Capricor Therapeutics Inc Earnings Call Summary for Q1/2026
- Capricor reported Q1 2026 EPS of -$0.59, missing estimates of -$0.52 by 13.46%; net loss widened to $33.9M amid increased investments
- Operating expenses surged 47.2% YoY to $36.8M as company invests in regulatory activities, manufacturing expansion, and commercial infrastructure
- Lead product deramiocel remains under FDA review with PDUFA date set for August 2026; no revenue expected until approval and launch
- Strong balance sheet with cash reserves sufficient to fund operations through Q4 2027; potential Priority Review Voucher upon approval
- Stock rose 0.6% post-earnings to $32.09 despite miss; analyst price targets range from $43-$63, reflecting confidence in regulatory progress
Last Updated: 12/05/2026, 23:00
Read Full TranscriptEarnings
Latest Release
May 12, 2026
EPS / Forecast
-0.59 / -0.52
Revenue / Forecast
-- / --
Compare CAPR to Peers and Sector
Metrics to compare | CAPR | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCAPRPeersSector | |
|---|---|---|---|---|
P/E Ratio | −9.9x | −1.7x | −0.4x | |
PEG Ratio | 0.16 | −0.04 | 0.00 | |
Price/Book | 4.1x | 1.9x | 2.6x | |
Price / LTM Sales | - | 11.6x | 3.0x | |
Upside (Analyst Target) | 169.2% | 291.8% | 54.6% | |
Fair Value Upside | Unlock | 26.4% | 9.7% | Unlock |
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial to treat SARS-CoV-2; StealthX Exosome Platform, and exosome platform program consists of engineered exosomes for vaccine and therapeutic development and is in preclinical trial. In addition, it engages in developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases; It has license agreement with Johns Hopkins University, University of Rome License, and Cedars-Sinai Medical Center to develop and commercialize licensed products and licensed services under the licensed patent rights in all fields and a nonexclusive right to the know-how; Cell Line License Agreement with Life Technologies for the development of exosomes platform. The company was founded in 2005 and is headquartered in San Diego, California.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Capricor Therapeutics (CAPR) Stock Price Today?
The Capricor Therapeutics stock price today is 19.500 USD.
What Stock Exchange Does Capricor Therapeutics Trade On?
Capricor Therapeutics is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Capricor Therapeutics?
The stock symbol for Capricor Therapeutics is "CAPR."
What Is the Capricor Therapeutics Market Cap?
As of today, Capricor Therapeutics market cap is 1.130B USD.
What Is Capricor Therapeutics's Earnings Per Share (TTM)?
The Capricor Therapeutics EPS (TTM) is -2.318.
When Is the Next Capricor Therapeutics Earnings Date?
Capricor Therapeutics will release its next earnings report on Aug 12, 2026.
From a Technical Analysis Perspective, Is CAPR a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Capricor Therapeutics Stock Split?
Capricor Therapeutics has split 2 times.
How Many Employees Does Capricor Therapeutics Have?
Capricor Therapeutics has 231 employees.
What is the current trading status of Capricor Therapeutics (CAPR)?
As of Jul 21, 2026, Capricor Therapeutics (CAPR) is trading at a price of 19.500 USD, with a previous close of 19.500 USD. The stock has fluctuated within a day range of 18.930 USD to 20.170 USD, while its 52-week range spans from 4.300 USD to 40.370 USD.
What Is Capricor Therapeutics (CAPR) Price Target According to Analysts?
The average 12-month price target for Capricor Therapeutics is 53.600 USD, with a high estimate of 63 USD and a low estimate of 38 USD. 10 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +174.87% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2026 - Fusion Media Limited. All Rights Reserved.